Literature DB >> 17264068

XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.

Geoffrey Liu1, Wei Zhou, Beow Y Yeap, Li Su, John C Wain, John M Poneros, Norman S Nishioka, Thomas J Lynch, David C Christiani.   

Abstract

DNA damage is important in the pathogenesis of esophageal adenocarcinoma (EA). Polymorphic variants in DNA repair genes may be modifiers of the risk of EA through their role in altering human host response to gastroesophageal acid reflux, a well-described risk factor for EA. We studied the role of genetic polymorphisms of two key DNA repair genes, xeroderma pigmentosum group D (XPD) (Asp312Asn and Lys751Gln) in the nucleotide excision repair (NER) pathway and X-ray repair cross-complementing gene 1 (XRCC1) (Arg399Gln) in the base excision repair (BER) pathway, in the development of EA in 183 cases and 336 frequency-matched controls for age, gender and race. Genomic DNA was extracted from blood samples. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained from logistic regression models, adjusted for body mass index at 18 years of age, smoking and alcohol exposure. The variant genotypes of XPD Lys751Gln polymorphism were associated with a higher risk of EA; the adjusted OR comparing Gln/Gln + Lys/Gln with Lys/Lys was 1.49 (95% CI: 1.02-2.14). Although no significant relationships were found for the XRCC1 Arg399Gln polymorphism alone, this polymorphism did modify the relationship between XPD Lys751Gln and EA risk; when both polymorphisms were evaluated together, adding the number of variant alleles of the two polymorphisms resulted in a significant trend (trend test, P = 0.008); compared with individuals with no variant alleles (n = 88), the adjusted ORs of developing EA are 1.49 (95% CI: 0.88-2.59), 1.69 (95% CI: 0.98-2.96) and 2.58 (95% CI: 1.31-5.06) for one (n = 195), two (n = 166) and three or four variant alleles (n = 70), respectively. No relationships were found for the XPD Asp312Asn polymorphism. We conclude that combined NER and BER pathways are important to the development of EA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264068     DOI: 10.1093/carcin/bgm020

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  29 in total

1.  XPD Lys751Gln polymorphism and esophageal cancer risk: a meta-analysis involving 2288 cases and 4096 controls.

Authors:  Ling Yuan; Dan Cui; Er-Jiang Zhao; Chen-Zhi Jia; Li-Dong Wang; Wei-Quan Lu
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group.

Authors:  H H Yoon; P Catalano; M K Gibson; T C Skaar; S Philips; E A Montgomery; M J Hafez; M Powell; G Liu; A A Forastiere; A B Benson; L R Kleinberg; K M Murphy
Journal:  Cancer Chemother Pharmacol       Date:  2011-02-01       Impact factor: 3.333

3.  XPD Asp312Asn polymorphism and esophageal cancer risk: an update meta-analysis based on 3928 cases and 6012 controls.

Authors:  Xu-Feng Guo; Jun Wang; Xiao-Fei Lei; Yan-Ping Zeng; Xiao-Guang Lv; Wei-Guo Dong
Journal:  Int J Clin Exp Med       Date:  2014-09-15

4.  Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma.

Authors:  Winson Y Cheung; Rihong Zhai; Penny Bradbury; Jessica Hopkins; Matthew H Kulke; Rebecca S Heist; Kofi Asomaning; Clement Ma; Wei Xu; Zhaoxi Wang; Suzanne Hooshmand; Li Su; David C Christiani; Geoffrey Liu
Journal:  Int J Cancer       Date:  2012-04-24       Impact factor: 7.396

Review 5.  Genetic factors in the pathogenesis of gastroesophageal reflux disease.

Authors:  Uday C Ghoshal; Dipti Chourasia
Journal:  Indian J Gastroenterol       Date:  2011-05-12

6.  MUTYH Tyr165Cys, OGG1 Ser326Cys and XPD Lys751Gln polymorphisms and head neck cancer susceptibility: a case control study.

Authors:  Tomasz Sliwinski; Karolina Przybylowska; Lukasz Markiewicz; Pawel Rusin; Wioletta Pietruszewska; Hanna Zelinska-Blizniewska; Jurek Olszewski; Alina Morawiec-Sztandera; Wojciech Mlynarski; Ireneusz Majsterek
Journal:  Mol Biol Rep       Date:  2010-06-23       Impact factor: 2.316

7.  XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.

Authors:  Da-Peng Ding; Wen-Li Ma; Xiao-Feng He; Ying Zhang
Journal:  Mol Biol Rep       Date:  2011-06-11       Impact factor: 2.316

8.  XRCC1 Arg399Gln, Arg194Trp, and Arg280His polymorphisms in esophageal cancer risk: a meta-analysis.

Authors:  Shan Li; Yan Deng; Jian-Peng You; Zhi-Ping Chen; Qi-Liu Peng; Xia-Mei Huang; Qing-Hua Lu; Xiu-Li Huang; Jin-Min Zhao; Xue Qin
Journal:  Dig Dis Sci       Date:  2013-03-30       Impact factor: 3.199

9.  Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.

Authors:  Penelope A Bradbury; Matthew H Kulke; Rebecca S Heist; Wei Zhou; Clement Ma; Wei Xu; Ariela L Marshall; Rihong Zhai; Susanne M Hooshmand; Kofi Asomaning; Li Su; Frances A Shepherd; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu
Journal:  Pharmacogenet Genomics       Date:  2009-08       Impact factor: 2.089

10.  A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.

Authors:  Fang Wen; Zhiyong Zhao; Chuan Liu; Qinghua Yin; Jie Weng; Yajie Wang; Yuchen Ma
Journal:  Tumour Biol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.